Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD

SINGAPORE, February 11 - The January issue of "Neuropharmacology", publishes the article entitled
"Neuroprotective and Neuroproliferative Activities of NeuroAiD", reporting
pharmacological data establishing NeuroAiD (MLC 601) protective effects on
neuronal and brain injuries as well as its effectiveness in neurological
functions recovery.

The French research team was led by Prof. Michel Lazdunski,
world-renowned specialist of pharmacology.

The data demonstrates NeuroAiD effects on decreasing cognitive deficits,
preventing death of threatened neuronal tissues and improving functional
outcomes by repairing and restoring neuronal circuits. This is fully
consistent with clinical observations of NeuroAiD efficacy as a post stroke
treatment.

NeuroAiD treatment increases survival rate, reduces infarct volume,
prevents neuronal death and drastically decreases functional deficits in
rodents' stroke models. The data also shows NeuroAiD effectiveness in
reducing stroke severity when administrated preventively.

The results show that NeuroAiD triggers the synthesis of Brain Derived
Neurotrophic Factor (BDNF), which is known to promote neuroplasticity. Indeed
NeuroAiD induces neurogenesis in rodent and human cells, and stimulates the
development of new neuronal circuits of information.

Previous trials and clinical reports conducted in Asia have already
demonstrated high levels of NeuroAiD safety and efficacy in improving stroke
rehabilitation, even when taken several months after stroke onset. NeuroAiD
Stroke Treatment is already available in many countries in Asia and in the
Middle East for stroke survivors. New clinical assessments will be conducted
in France and Europe shortly on stroke recovery.

David Picard, CEO of Moleac, said "We are extremely enthusiastic and
proud to see these data published. It is a strong validation of our research
of active ingredients in NeuroAiD as well as of our efforts towards
continuous optimization of its formula. These results pave the way for new
indications of NeuroAiD beyond stroke recovery such as prevention, cognitive
impairments and dementia. It is good news for patients who are in need of
treatment in this under-served therapeutic area."

About Moleac

Moleac is a Singapore-based biopharmaceutical company that dedicates
itself in finding and developing new medicines for the unmet needs of
patients worldwide. www.moleac.net

About NeuroAiD

NeuroAiD is a stroke treatment to help stroke patients achieve faster and
better recovery. NeuroAiD is derived from natural components, carefully
selected for their efficacy and absence of side effects. It currently reaches
out to patients in over 25 countries. www.neuroaid.com

    Contact details:

     Kasia Kaminska
     Tel: +65-64789432
     Kasia.kaminska@moleac.net

Kasia Kaminska +65-64789432, Kasia.kaminska at moleac.net